Bidard FC, Jacot W, Dureau S. et al.
Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial.
San Antonio Breast Cancer Symposium 2018; Abstr. GS3-07
Download Bibliographical Data